fbpx Skip to main content
 

Search

Janssen Search

Search results

6 SEARCH RESULTS FOR

xarelto

Not finding what you're looking for? Visit Janssen in your country.
PAGE 1 OF 1

Moving Forward for Cardiovascular Disease Patients and Their Doctors At Janssen, nothing is more important to us than the health and safety of the patients who use our medicines, and we take any allegations regarding the science, safety and efficacy of ...

Mar 05, 2023 United States Findings presented at ACC.23 show XARELTO ® plus aspirin provides a 33 percent reduction in acute limb ischemia following LER, with consistent benefit demonstrated at 30 days, 90 days and up to three years Patients who undergo ...

Dec 09, 2022 United States Head-to-head observational analysis showed XARELTO ® as effective in treating cancer-associated thromboembolism (CAT) as apixaban Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer 1   ...

May 23, 2022 United States COMPASS open label extension study results support the long-term use of XARELTO ®  plus aspirin for vascular protection in patients with chronic CAD and/or PAD XATOA registry provides further evidence of the benefit of DPI for ...

RICHARD APPIAH VICE PRESIDENT DISEASE AREA COMMERCIAL LEADER GASTROENTEROLOGY Richard Appiah is Vice President, Disease Area Commercial Leader, Gastroenterology for the Immunology Therapeutic Area at Janssen Global Services. In this role, he is ...

NAUMAN SHAH GLOBAL HEAD JANSSEN BUSINESS DEVELOPMENT Nauman Shah is Global Head, Janssen Business Development. In this role, Nauman leads the Janssen Business Development organization in the identification, evaluation, execution, integration and ...

6 SEARCH RESULTS FOR

xarelto

Not finding what you're looking for? Visit Janssen in your country.
PAGE 1 OF 1